Chen LeiLei, Wang Jingshi, Wang Zhao
Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China.
Infect Drug Resist. 2024 Apr 18;17:1545-1550. doi: 10.2147/IDR.S441460. eCollection 2024.
Hemophagocytic lymphohistiocytosis (HLH), whether primary or secondary, is a rare and fatal clinical syndrome of uncontrolled immune activation and inflammatory cascade. Immune checkpoint inhibitors (ICIs) induced HLH has no standard diagnostic and treatment guidelines. Early diagnosis and appropriate treatment according to different disease backgrounds are crucial. Herein, we first report 2 cases of patients with chronic active Epstein-Barr virus infection (CAEBV) who developed HLH after the use of sintilimab, a monoclonal antibody against programmed cell death protein 1 (PD-1), and the DEP (liposomal doxorubicin, etoposide, methylprednisolone) chemotherapy regimen in combination with ruxolitinib were used to successfully control the disease.
噬血细胞性淋巴组织细胞增生症（HLH），无论是原发性还是继发性，都是一种罕见且致命的临床综合征，其特征为免疫激活和炎症级联反应失控。免疫检查点抑制剂（ICI）诱导的HLH尚无标准的诊断和治疗指南。根据不同的疾病背景进行早期诊断和适当治疗至关重要。在此，我们首次报告2例慢性活动性EB病毒感染（CAEBV）患者，他们在使用抗程序性细胞死亡蛋白1（PD-1）单克隆抗体信迪利单抗后发生了HLH，并采用了DEP（脂质体阿霉素、依托泊苷、甲泼尼龙）化疗方案联合鲁索替尼成功控制了病情。
